Fresenius Medical Care announced strong financial results for the third quarter of 2024, with operating income increasing by 43% to EUR 463 million, or 43% at constant currency. The operating income margin reached 9.7%, demonstrating meaningful progress towards the company's 2025 margin targets. This growth was supported by positive price and volume effects, as well as the phasing of a consent agreement on certain pharmaceuticals.
The company's FME25 transformation program continued to gain momentum, delivering EUR 64 million in additional sustainable savings during the quarter, bringing year-to-date savings to EUR 173 million. Fresenius Medical Care confirmed its target of EUR 650 million in sustainable savings by 2025. Care Delivery's operating income margin expanded to 11.1%, while Care Enablement's operating income significantly increased to EUR 61 million from EUR -1 million in the prior year.
Fresenius Medical Care confirmed its full-year 2024 revenue growth outlook and tightened its operating income growth outlook to 16-18%, moving towards the upper end of the previous range. The net leverage ratio improved to 2.8x, and operating cash flow increased by 30% to EUR 985 million, largely due to the recovery of cash impact following the Change Healthcare cyber incident.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.